Search Results (1,208)

Cell-based therapeutics are redefining interventions for vision loss by enabling tissue replacement, regeneration, and neuroprotection. This review surveys contemporary cellular strategies in ophthalmology through the lenses of therapeutic effectiveness, translational readiness, and governance. We profile principal sources—embryonic and induced pluripotent stem cells, mesenchymal stromal cells, retinal pigment epithelium, retinal progenitor and limbal stem cells—and enabling platforms including extracellular vesicles, encapsulated cell technology and biomaterial scaffolds. We synthesize clinical evidence across age-related macular degeneration, inherited retinal dystrophies, and corneal injury/limbal stem-cell deficiency, and highlight emerging applications for glaucoma and diabetic retinopathy. Delivery routes (subretinal, intravitreal, anterior segment) and graft formats (single cells, sheets/patches, organoids) are compared using standardized structural and functional endpoints. Persistent barriers include GMP-compliant derivation and release testing; differentiation fidelity, maturation, and potency; genomic stability and tumorigenicity risk; graft survival, synaptic integration, and immune rejection despite ocular immune privilege; the scarcity of validated biomarkers and harmonized outcome measures and ethical, regulatory, and health-economic constraints. Promising trajectories span off-the-shelf allogeneic products, patient-specific iPSC-derived grafts, organoid and 3D-bioprinted tissues, gene-plus-cell combinations, and cell-free extracellular-vesicle therapeutics. Overall, cell-based therapies remain investigational. With adequately powered trials, methodological harmonization, long-term surveillance, scalable xeno-free manufacturing, and equitable access frameworks, they may eventually become standards of care; at present, approvals are limited to specific products/indications and regions, and no cell therapy is the standard of care for retinal disease. Full article

Background: Traditional parameters such as bone-to-implant contact percentage (BIC%) provide only static insights into implant integration and do not reflect the temporal dynamics of bone regeneration. The concept of Dynamic Regenerative Balance (DRB) was introduced to represent the biological equilibrium between bone formation and graft resorption. The break-even point serves as a measurable approximation of this equilibrium. This study aimed to illustrate the usefulness of the break-even point in expressing the balance between graft resorption and new bone formation, rather than to define definitive values for specific biomaterials. Methods: Four preclinical studies on sinus floor elevation in rabbits were selected. Each reported histomorphometric data on new bone formation and graft resorption at two or more time points. Six biomaterials were analyzed: autogenous bone, Bio-Oss^®, Bio-Oss Collagen^®, Gen-Os^®, Maxresorb^®, and Maxresorb^® Inject. The break-even point was calculated by linear extrapolation as the time at which new bone equals residual graft percentage. Results: The break-even point varied significantly among biomaterials (expressed in days/area %): autogenous bone reached equilibrium fastest (18.4 days/13.5%), followed by Gen-Os^® (40.4 d/19.1%). Bio-Oss Collagen^® (62.3 d/28.3%), Maxresorb^® (73.9 d/36.4%), and Maxresorb^® Inject (96.1 d/34.1%). For Bio-Oss^®, it occurred at 81.8 days (33.6%) in one study, while in another, it was not reached within 6 months. These differences reflect distinct regenerative kinetics and resorption profiles among materials. Conclusions: The break-even point offers a simple and informative parameter to describe the balance between graft resorption and new bone formation, providing a useful complement to conventional histomorphometric measures and a framework for future studies. Full article

The tumor microenvironment (TME) plays a crucial role in regulating cancer cell proliferation, invasion, and drug resistance. Traditional two-dimensional (2D) in vitro models and animal models often fail to replicate the biochemical and biophysical complexity of human tumors, leading to low predictive power in preclinical drug screening. In recent years, scaffold-based three-dimensional (3D) in vitro models have emerged as promising alternatives, offering a more physiologically relevant context for studying tumor behavior. Among these, biomimetic scaffolds capable of replicating the composition, stiffness, porosity, and signaling features of the tumor extracellular matrix (ECM) are of particular interest. This review provides a comprehensive overview of scaffold-based approaches for mimicking the TME in vitro. After outlining the key characteristics of the tumor ECM, we discuss various scaffold typologies, including those based on natural, synthetic, and hybrid biomaterials, as well as decellularized ECM. Recent advancements in fabrication technologies, such as electrospinning and 3D bioprinting, are also highlighted for their role in replicating the geometric and mechanical features of tumor tissues. Special attention is given to the integration of vascular components and stromal cells to recapitulate the complexity of the TME. Finally, we explore current limitations and future directions, emphasizing the need for standardized and reproducible models, particularly in the context of personalized cancer therapy. Full article

Wound healing is a dynamic process involving distinct phases that are regulated by cellular and molecular interactions. This review explores the fundamental mechanisms involved in wound healing, including the roles of cytokines and growth factors within the local microenvironment, with a particular focus on antimicrobial peptides (AMPs) as immune modulators and therapeutic agents in chronic wounds. Notably, AMPs such as LL-37 have been shown to reduce biofilm density by up to 60%, highlighting their dual role in both modulating host immune responses and combating persistent bacterial infections. It further examines emerging technologies that are transforming the field, extending beyond traditional biological mechanisms to innovations such as smart dressings, 3D bioprinting, AI-driven therapies, regenerative medicine, gene therapy, and organoid models. Additionally, the review addresses strategies to overcome bacterial biofilms and highlights promising approaches including biomaterials, nanomedicine, gene therapy, peptide-loaded nanoparticles, and the application of organoids as advanced platforms for studying and enhancing wound repair. Full article

Pulmonary fibrosis (PF) is a progressive and fatal lung disease characterized by irreversible alveolar destruction and pathological extracellular matrix (ECM) deposition. Currently approved agents (pirfenidone and nintedanib) slow functional decline but do not reverse established fibrosis or restore functional alveoli. Multifunctional bioscaffolds present a promising therapeutic strategy through targeted modulation of critical cellular processes, including proliferation, migration, and differentiation. This review synthesizes recent advances in scaffold-based interventions for PF, with a focus on their dual mechano-epigenetic regulatory functions. We delineate how scaffold properties (elastic modulus, stiffness gradients, dynamic mechanical cues) direct cell fate decisions via mechanotransduction pathways, exemplified by focal adhesion–cytoskeleton coupling. Critically, we highlight how pathological mechanical inputs establish and perpetuate self-reinforcing epigenetic barriers to regeneration through aberrant chromatin states. Furthermore, we examine scaffolds as platforms for precision epigenetic drug delivery, particularly controlled release of inhibitors targeting DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) to disrupt this mechano-reinforced barrier. Evidence from PF murine models and ex vivo lung slice cultures demonstrate scaffold-mediated remodeling of the fibrotic niche, with key studies reporting substantial reductions in collagen deposition and significant increases in alveolar epithelial cell markers following intervention. These quantitative outcomes highlight enhanced alveolar epithelial plasticity and upregulating antifibrotic gene networks. Emerging integration of stimuli-responsive biomaterials, CRISPR/dCas9-based epigenetic editors, and AI-driven design to enhance scaffold functionality is discussed. Collectively, multifunctional bioscaffolds hold significant potential for clinical translation by uniquely co-targeting mechanotransduction and epigenetic reprogramming. Future work will need to resolve persistent challenges, including the erasure of pathological mechanical memory and precise spatiotemporal control of epigenetic modifiers in vivo, to unlock their full therapeutic potential. Full article

Wound healing remains a significant clinical challenge due to antibiotic-resistant pathogens, persistent inflammation, oxidative stress, and impaired tissue regeneration. Conventional therapies are often inadequate, necessitating alternative strategies. Plant bioactive compounds, including flavonoids, tannins, terpenoids, and alkaloids, offer antimicrobial, anti-inflammatory, antioxidant, and pro-angiogenic properties that directly address these challenges in wound healing therapy. However, their poor solubility, instability, and rapid degradation at the wound site limit clinical translation. Biomaterial-based scaffolds such as hydrogels, electrospun nanofibers, lyophilized dressings, and 3D-bioprinted constructs have emerged as promising delivery platforms to enhance bioavailability, stability, and sustained release of bioactive compounds while providing structural support for cell adhesion, proliferation, and tissue repair. This review was conducted through a structured literature search using PubMed, Scopus, and Web of Science databases, covering studies published between 1998 and 2025, with keywords including wound healing, phytochemicals, plant bioactive compounds, scaffolds, hydrogels, electrospinning, and 3D bioprinting. The findings highlight how incorporation of plant bioactive compounds onto scaffolds can combat resistant microbial infections, mitigate oxidative stress, promote angiogenesis, and accelerate tissue regeneration. Despite these promising outcomes, further optimization of scaffold design, standardization of bioactive formulations, and translational studies are needed to bridge laboratory research with clinical applications for next generation wound healing therapies. Full article

Background: Excessive scarring remains a frequent complication in plastic surgery, yet standardized preventive strategies are lacking. Type I collagen-based biomaterials may support regenerative processes and improve scar outcomes. Methods: This case series includes six female patients (ages 24–52) undergoing wound management after trauma and procedures including blepharoplasty, abdominoplasty, and revision mammaplasty. Native collagen type I (7% or 15%) was injected along wound margins or into hypertrophic scars at 3–4 week intervals. Outcomes were assessed through patient-reported symptoms and Antera 3D imaging (vascularity, pigmentation, surface topography). Results: Patients reported reduced tightness, pruritus, and scar stiffness after initial sessions. Antera 3D imaging showed decreased vascular and pigment indices, and a reduction in surface elevation over follow-up (up to 14 months). No adverse effects such as atrophy or infection were observed. Conclusions: Native type I collagen was well tolerated and may be a useful adjunct for wound healing and scar modulation following plastic surgery. Full article

Background: The implant–abutment interface has been thoroughly examined due to its impact on the success of implant healing and longevity. Removing the abutment is advantageous, but it changes the biomechanics of the implant fixture and restoration. This in vitro three-dimensional finite element analytical (FEA) study aims to evaluate the distribution of von Mises stress (VMS) in abutment-free and three additional implant abutment connections composed of various titanium alloys. Materials and methods: A three-dimensional implant-supported single-crown prosthesis model was digitally generated on the mandibular section using a combination of microcomputed tomography imaging (microCT), a computer-assisted designing (CAD) program (SolidWorks), Analysis of Systems (ANSYS), and a 3D digital scan (Visual Computing Lab). Four digital models [A (BioHorizons), B (Straumann AG), C abutment-free (Matrix), and D (TRI)] representing three different functional biomaterials [wrought Ti-6Al-4Va ELI, Roxolid (85% Ti, 15% Zr), and Ti-6Al-4V ELI] were subjected to simulated static/cyclic static loading in axial/oblique directions after being restored with highly translucent monolithic zirconia restoration. The stresses generated on the implant fixture, abutment, crown, screw, cortical, and cancellous bones were measured. Results: The highest VMSs were generated by the abutment-free (Model C, Matrix) implant system on the implant fixture [static (32.36 Mpa), cyclic static (83.34 Mpa)], screw [static (16.85 Mpa), cyclic static (30.33 Mpa), oblique (57.46 Mpa)], and cortical bone [static (26.55), cyclic static (108.99 Mpa), oblique (47.8 Mpa)]. The lowest VMSs in the implant fixture, abutment, screw, and crown were associated with the binary alloy Roxolid [83–87% Ti and 13–17% Zr]. Conclusions: Abutment-free implant systems generate twice the stress on cortical bone than other abutment implant systems while producing the highest stresses on the fixture and screw, therefore demanding further clinical investigations. Roxolid, a binary alloy of titanium and zirconia, showed the least overall stresses in different loadings and directions. Full article

Bone regeneration depends on a delicate balance between osteoblast-driven bone formation and osteoclast-mediated resorption, coordinated by complex biochemical cues. Magnesium (Mg²⁺) is known to modulate these processes. However, despite extensive research, its ability to simultaneously enhance osteogenesis and inhibit osteoclast activity remains unclear. In this study, we first investigated the effect of extracellular Mg²⁺ (0, 5, 10, 25, 50 mM) on osteoblast and osteoclast differentiation in 2D culture to determine whether a single Mg²⁺ dosing regimen can simultaneously promote osteogenesis while inhibiting osteoclast differentiation and maturation. A concentration dependent effect of Mg²⁺ was observed on both cell types, with increasing Mg²⁺ concentrations up to 25 mM significantly reducing osteoclast formation yet concurrently inhibiting osteogenic differentiation. At 50 mM, Mg²⁺ exhibited cytotoxic effects on both cell types. We then leveraged the osteogenic properties of biomimetic collagen/nano-hydroxyapatite (Coll/nHA) scaffolds by incorporating Mg²⁺ into the nHA phase to enable localised, controlled delivery. At a scaffold-loaded equivalent of 25 mM Mg²⁺, we observed enhanced bone matrix deposition alongside reduced osteoclast maturation, indicating a synergistic effect between Mg²⁺ and nHA in promoting osteogenesis. While no optimal synergistic dose was identified in 2D culture, these findings demonstrate that Coll-nHA scaffolds offer a promising strategy for localised Mg²⁺ delivery to enhance osteogenesis and suppress osteoclastogenesis. Importantly, the ease of scaffold modification opens the door to incorporating additional bioactive molecules, further advancing their potential in bone tissue engineering applications and the development of next-generation biomaterials for bone regeneration. Full article

Dynamic hydrogels are revolutionizing tumor microenvironment (TME) engineering through their stimuli-responsive adaptability, mechanical tunability, and capacity for multifunctional integration. In addition, they are excellent biomaterials for cancer treatments, including their biomimetic properties and controlled cargo release capability. This review introduces the rational design and principles of dynamic hydrogels for recreating the tumor microenvironment and cancer therapy, including natural/synthetic hydrogels, multi-stimuli responsive hydrogels, and multi-drug loading hydrogels. These designs emphasize their unique roles in overcoming drug resistance, enhancing immunotherapy, and enabling patient-specific models. We highlight breakthroughs such as dual-responsive nanocomposites and microfluidic-integrated 3D platforms while addressing translational hurdles like cytotoxicity and regulatory delays. By proposing strategies to bridge material science with clinical needs, this work positions dynamic hydrogels as pivotal tools for next-generation precision oncology. Full article

Three-dimensional (3D) bioprinting has become one of the most advanced and useful innovations that allows the creation of personalized macroscopic and microscopic constructs at different scales that match a patient’s anatomy. Intensive research efforts are currently underway to develop highly printable and biocompatible materials. Among the variety of bioprinting materials (i.e., biomaterial inks), naturally derived hydrogels have attracted great interest due to their beneficial properties in terms of biocompatibility, cost-effectiveness, and biodegradability. In this proceeding paper, we provide an overview of the formulation and use of three functional polysaccharides as ink-based hydrogels. First, 3D bioprinting is summarized as revolutionary technology that is able to create cell-laden structures layer by layer in a specific pattern that mimics native tissue and organs. Cellulose, chitosan, and lignin are presented below, followed by an overview of their applicability in 3D bioprinting, focusing on printability and the resulting printed 3D structures as illustrated in various published figures. In the same way, a comparative overview of 3D bioprinting applications is summarized. Finally, a section dedicated to comparisons, limitations, and crosslinking strategies is provided. It is worth noting that this proceedings paper provides a brief overview rather than a comprehensive review, as it is limited by page constraints and is based on the content of our poster presented at the 1st International Online Conference on Bioengineering. Full article

The increasing demand for novel tissue engineering (TE) applications in bone tissue regeneration underscores the importance of exploring advanced manufacturing techniques and biomaterials for personalised treatment approaches. Three-dimensional printing (3DP) technology facilitates the development of implantable devices with intricate geometries, enabling patient-specific therapeutic solutions. Although Fused Filament Fabrication (FFF) and Direct Ink Writing (DIW) are widely utilised for fabricating bone-like implants, the need for multiple processing steps often prolongs the overall production time. In this study, a single-step melt-extrusion 3DP technique was performed to develop multi-material scaffolds including bioceramics, hydroxyapatite (HA), and β-tricalcium phosphate (TCP) in both their bioactive and calcined forms at 10% and 20% w/w, within polycaprolactone (PCL) matrices. Printing parameters were optimised, and physicochemical properties of all biomaterials and final forms were evaluated. Thermal degradation and surface morphology analyses assessed the consistency and distribution of the ceramics across the different formulations. The tensile testing of the scaffolds defined the impact of each ceramic type and wt% on scaffold flexibility performance, while in vitro cell studies determined the cytocompatibility efficiency. Hence, all 3D-printed PCL–ceramic composite scaffolds achieved structural integrity and physicochemical and thermal stability. The mechanical profile of extruded samples was relevant to the ceramic consistency, providing valuable insights for further mechanotransduction investigations. Notably, all materials showed high cell viability and proliferation, indicating strong biocompatibility. Therefore, this additive manufacturing (AM) process is a precise and fast approach for developing biomaterial-based scaffolds, with potential applications in surgical restoration and support of segmental bone defects. Full article

The growing threat of Antimicrobial Resistance (AMR) demands innovative drug discovery, yet conventional 2D cell cultures fail to accurately mimic in vivo conditions, leading to high failure rates in preclinical studies. This review addresses the critical need for more physiologically relevant platforms by exploring recent advancements in bioengineered 3D tissue models for studying bacterial pathogenesis and antimicrobial drug discovery. We conducted a systematic search of peer-reviewed articles from 2015 to 2025 across PubMed, Scopus, and Web of Science, focusing on studies that used 3D models to investigate host–pathogen interactions or antimicrobial screening. Data on model types, biomaterials, fabrication techniques, and key findings were systematically charted to provide a comprehensive overview. Our findings reveal that a diverse range of biomaterials, including biopolymers and synthetic polymers, combined with advanced techniques like 3D bioprinting, are effectively used to create sophisticated tissue scaffolds. While these 3D models demonstrate clear superiority in mimicking biofilm properties and complex host–pathogen dynamics, our analysis identified a significant research gap: very few studies directly integrate these advanced bioengineered 3D models for high-throughput antimicrobial drug discovery. In conclusion, this review highlights the urgent need to bridge this disparity through increased research, standardization, and scalability in this critical interdisciplinary field, with the ultimate goal of accelerating the development of new therapeutics to combat AMR. Full article

Background: Spinal deformity correction surgery, particularly in scoliosis, often necessitates long fusion constructs and complex osteotomies that create significant structural bone defects. These defects threaten the integrity of spinal fusion, potentially compromising surgical outcomes. Bone grafting remains the cornerstone of addressing these defects, traditionally relying on autologous bone. However, limitations such as donor site morbidity and insufficient graft volume have made urgent the development and adoption of biologic substitutes and synthetic alternatives. Additionally, innovations in three-dimensional (3D) printing offer emerging solutions for graft customization and improved osseointegration. Objective: This scoping review maps the evidence of the effectiveness of the use of biologic and synthetic bone grafts in scoliosis surgery. It focusses on the role of novel technologies, particularly osteobiologics in combination with 3D-printed scaffolds, in enhancing graft performance and surgical outcomes. Methods: A comprehensive literature search was conducted using PubMed, Scopus, and the Cochrane Library to identify studies published within the last 15 years. Inclusion criteria focused on clinical and preclinical research involving biologic grafts (e.g., allografts, demineralized bone matrix-DBM, bone morphogenetic proteins-BMPs), synthetic substitutes (e.g., ceramics, polymers), and 3D-printed grafts in the context of scoliosis surgery. Data were extracted on graft type, clinical application, outcome measures, and complications. The review followed PRISMA-ScR guidelines and employed the Arksey and O’Malley methodological framework. Results: The included studies revealed diverse grafting strategies across pediatric and adult populations, with varying degrees of fusion success, incorporation rates, and complication profiles. It also included some anime studies. Emerging 3D technologies demonstrated promising preliminary results but require further validation. Conclusions: Osteobiologic and synthetic bone grafts, including those enhanced with 3D technologies, represent a growing area of interest in scoliosis surgery. Despite promising outcomes, more high-quality comparative clinical studies are needed to guide clinical decision-making and standardize practice. Full article

Background/Objectives: Mesenchymal stem cells (MSCs) offer promising prospects for novel treatment modalities in cellular therapies and artificial organ production. Despite a surge in artificial tissue research, there is a dearth of comprehensive studies detailing the entire process from stem cells to tissue production, coupled with a scarcity. This study, however, presents the utility of extra-embryonic MSCs derived from placental tissue, traditionally considered as medical waste. Methods: Within a 3-dimensional cell culture system, histological assessments, and comprehensive optimization studies, the entire process required for artificial tissue production is addressed. Results: The results obtained are encouraging regarding the advancement of cellular therapies and artificial tissue engineering. However, challenges such as biopolymer degradation highlight the necessity for multistep approaches. Each analysis within this study delves into the discussion and optimization of key steps in artificial tissue production. Conclusions: Consequently, this study not only represents one of the first of its kind but also lays the groundwork for future investigations into relevant clinical applications. Full article